Show simple item record

dc.contributor.authorGrothey, A
dc.contributor.authorSobrero, A
dc.contributor.authorShields, A
dc.contributor.authorYoshino, T
dc.contributor.authorPaul, J
dc.contributor.authorTaieb, J
dc.contributor.authorSouglakos, J
dc.contributor.authorShi, Q
dc.contributor.authorKerr, R
dc.contributor.authorLabianca, R
dc.contributor.authorMeyerhardt, J
dc.contributor.authorVernerey, D
dc.contributor.authorYamanaka, T
dc.contributor.authorBoukovinas, I
dc.contributor.authorMeyers, J
dc.contributor.authorRenfro, L
dc.contributor.authorNiedzwiecki, D
dc.contributor.authorWatanabe, T
dc.contributor.authorTorri, V
dc.contributor.authorSaunders, Mark P
dc.contributor.authorSargent, D
dc.contributor.authorAndre, T
dc.contributor.authorIveson, T
dc.date.accessioned2018-04-30T21:01:46Z
dc.date.available2018-04-30T21:01:46Z
dc.date.issued2018
dc.identifier.citationDuration of adjuvant chemotherapy for stage III colon cancer. 2018, 378(13): 1177-1188 N Engl J Meden
dc.identifier.issn1533-4406
dc.identifier.pmid29590544
dc.identifier.doi10.1056/NEJMoa1713709
dc.identifier.urihttp://hdl.handle.net/10541/620929
dc.description.abstractSince 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures.
dc.language.isoenen
dc.rightsArchived with thanks to The New England journal of medicineen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCapecitabine
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshClinical Trials, Phase III as Topic
dc.subject.meshColonic Neoplasms
dc.subject.meshDisease-Free Survival
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshHumans
dc.subject.meshIntention to Treat Analysis
dc.subject.meshLeucovorin
dc.subject.meshMale
dc.subject.meshMedication Adherence
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshNeoplasm Staging
dc.subject.meshNervous System Diseases
dc.subject.meshOrganoplatinum Compounds
dc.subject.meshProportional Hazards Models
dc.subject.meshProspective Studies
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshYoung Adult
dc.titleDuration of adjuvant chemotherapy for stage III colon cancer.en
dc.typeArticleen
dc.contributor.departmentMedical Oncology, Mayo Clinic, Rochester, MNen
dc.identifier.journalThe New England Journal of Medicineen
refterms.dateFOA2020-05-01T14:52:43Z
html.description.abstractSince 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures.


Files in this item

Thumbnail
Name:
160340.pdf
Size:
287.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record